The benefit of docosahexaenoic acid for the adult brain in aging and dementia

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 92, Issue , 2015, Pages 15-22

  Salem, Norman ^a   Vandal, Milene ^b,c   Calon, Frederic ^b,c  

^a DSM Nutritional Lipids   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Aging; Alzheimer's disease; ApoE; Cognition; Dementia; Docosahexaenoic acid

Indexed keywords

APOLIPOPROTEIN E4; DOCOSAHEXAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; NEUROPROTECTIVE AGENT;

AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; BRAIN METABOLISM; COGNITION; DEMENTIA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; EPISODIC MEMORY; FAT INTAKE; GAIN OF FUNCTION MUTATION; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; LOSS OF FUNCTION MUTATION; MEMORY DISORDER; METABOLIC REGULATION; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ANIMAL; BRAIN; DRUG EFFECTS; PATHOPHYSIOLOGY;

AGING; ANIMALS; BRAIN; COGNITION; DEMENTIA; DOCOSAHEXAENOIC ACIDS; HUMANS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921439513     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.10.003     Document Type: Article

References (148)

1. Beydoun M.A., Kaufman J.S., Satia J.A., et al. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the atherosclerosis risk in communities study. Am. J. Clin. Nutr. 2007, 85(4):1103-1111.
2. Heude B., Ducimetière P., Berr C. Cognitive decline and fatty acid composition of erythrocyte membranes - the EVA study. Am. J. Clin. Nutr. 2003, 77(4):803-808.
3. Conquer J.A., Tierney M.C., Zecevic J., et al. Fatty acid analysis of blood plasma of patients with Alzheimer[U+05F3]s disease, other types of dementia, and cognitive impairment. Lipids 2000, 35(12):1305-1312.
4. Schaefer E.J., Bongard V., Beiser A.S., et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol. 2006, 63(11):1545-1550.
5. van de Rest O., Spiro A., Krall-Kaye E., et al. Intakes of (n-3) fatty acids and fatty fish are not associated with cognitive performance and 6-year cognitive change in men participating in the Veterans Affairs Normative Aging Study. J. Nutr. 2009, 139(12):2329-2336.
6. Barberger-Gateau P., Letenneur L., Deschamps V., et al. Fish, meat, and risk of dementia: cohort study. Br. Med. J. 2002, 325(7370):932-933.
7. Morris M.C., Evans D.A., Bienias J.L., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003, 60(7):940-946.
8. Cederholm T., Salem N., Palmblad J. Omega-3 fatty acids in the prevention of cognitive decline in humans. Adv. Nutr. (Bethesda, Md) 2013, 4(6):672-676.
9. Marszalek J.R., Lodish H.F. Docosahexaenoic acid, fatty acid-interacting proteins, and neuronal function: breastmilk and fish are good for you. Annu. Rev. Cell Dev. Biol. 2005, 21:633-657.
10. Barberger-Gateau P., Raffaitin C., Letenneur L., et al. Dietary patterns and risk of dementia: the three-city cohort study. Neurology 2007, 69(20):1921-1930.
11. Huang T.L., Zandi P.P., Tucker K.L., et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005, 65(9):1409-1414.
12. Whalley L.J., Deary I.J., Starr J.M., et al. n-3 Fatty acid erythrocyte membrane content, APOE epsilon 4, and cognitive variation: an observational follow-up study in late adulthood. Am. J. Clin. Nutr. 2008, 87(2):449-454.
13. Raji C.A., Erickson K.I., Lopez O.L., Kuller L.H., Gach H.M., Thompson P.M., et al. Regular fish consumption and age-related brain gray matter loss. Am. J. Prev. Med. 2014, 47:444-451.
14. Daiello L.A., Gongvatana A., Dunsiger S., Cohen R.A., Ott B.R. Association of fish oil supplement use with preservation of brain volume and cognitive function. Alzheimers Dement. 2014, (Epub ahead of print).
15. Yurko-Mauro K., Mccarthy D., Rom D., et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010, 6(6):456-464.
16. Benton D., Donohoe R.T., Clayton D.E., et al. Supplementation with DHA and the psychological functioning of young adults. Br. J. Nutr. 2013, 109(1):155-161.
17. Jackson P.A., Deary M.E., Reay J.L., et al. No effect of 12 weeks and apos; supplementation with 1g DHA-rich or EPA-rich fish oil on cognitive function or mood in healthy young adults aged 18-35 years. Br. J. Nutr. 2012, 107(8):1232-1243.
18. Quinn J.F., Raman R., Thomas R.G., et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. J. Am. Med. Assoc. 2010, 304(17):1903-1911.
19. Dangour A.D., Allen E., Elbourne D., et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am. J. Clin. Nutr. 2010, 91(6):1725-1732.
20. Stonehouse W., Conlon C.A., Podd J., et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am. J. Clin. Nutr. 2013, 97(5):1134-1143.
21. Stough C., Downey L., Silber B., et al. The effects of 90-day supplementation with the omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. Neurobiol. Aging 2012, 33(4).
22. Lee L.K., Shahar S., Chin A.-V., et al. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology. (Berl). 2013, 225(3):605-612.
23. Witte A.V., Kerti L., Hermannstadter H.M., Fiebach J.B., Schreiber S.J., Schuchardt J.P., et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb. cortex 2013, ([Epub ahead of print]).
24. Henderson S.T., Vogel J.L., Barr L.J., Garvin F., Jones J.J., Costantini L.C. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer[U+05F3]s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. (Lond) 2009, 6:31.
25. Relkin N. Clinical trials of intravenous immunoglobulin for Alzheimer[U+05F3]s disease. J. Clin. Immunol. 2014, 34:S74-S79.
26. Salloway S., Sperling R., Fox N.C., Blennow K., Klunk W., Raskind, Sabbagh M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer[U+05F3]s disease. N. Engl. J. Med. 2014, 370:322-333.
27. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., Roses A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer[U+05F3]s disease. Pharmacogenomics J. 2006, 6:246-254.
28. Donnelly L.A., Palmer C.N., Whitley A.L., Lang C.C., Doney A.S., Morris A.D., Donnan P.T. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet. Genomics. 2008, 18:279-287.
29. Harrington C., Sawchak S., Chiang C., Davies J., Donovan C., Saunders A.M., Irizarry M., et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer[U+05F3]s disease: two phase 3 studies. Curr. Alzheimer Res. 2011, 8:592-606.
30. Sano M., Bell K.L., Galasko D., Galvin J.E., Thomas R.G., van Dyck C.H., Aisen P.S. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011, 77:556-563.
31. Noetzli M., Eap C.B. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer[U+05F3]s disease. Clin. Pharmacokinet. 2013, 52:225-241.
32. Farrer L.A., Cupples L.A., Haines J.L., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. J. Am. Med. Assoc. 1997, 278(16):1349-1356.
33. Hauser P.S., Narayanaswami V., Ryan R.O., Apolipoprotein E. from lipid transport to neurobiology. Prog Lipid Res. 2011, 50(1):62-74.
34. Leduc V., Jasmin-Belanger S., Poirier J. APOE and cholesterol homeostasis in Alzheimer[U+05F3]s disease. Trends Mol. Med. 2010, 16(10):469-477.
35. Ward A., Crean S., Mercaldi C.J., et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer[U+05F3]s disease: a systematic review and meta-analysis. Neuroepidemiology 2012, 38(1):1-17.
36. Teter B. Life-span influences of apoE4 on CNS function. Neurobiol. Aging 2007, 28(5):693-703.
37. Pitas R.E., Boyles J.K., Lee S.H., et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J. Biol. Chem. 1987, 262(29):14352-14360.
38. Aoki K., Uchihara T., Sanjo N., et al. Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke 2003, 34(4):875-880.
39. Bu G. Apolipoprotein E and its receptors in Alzheimer[U+05F3]s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10(5):333-344.
40. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer[U+05F3]s disease. Neuron 2009, 63(3):287-303.
41. Mahley R.W., Huang Y. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 2012, 76(5):871-885.
42. Näslund J., Thyberg J., Tjernberg L.O., et al. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer[U+05F3]s disease brain. Neuron 1995, 15(1):219-228.
43. Strittmatter W.J., Huang D.Y., Bhasin R., et al. Avid binding of beta A amyloid peptide to its own precursor. Exp. Neurol. 1993, 122(2):327-334.
44. Strittmatter W.J., Weisgraber K.H., Huang D.Y., et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. 1993, 90(17):8098-8102.
45. Beffert U., Cohn J.S., Petit-Turcotte C., et al. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer[U+05F3]s disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999, 843(1-2):87-94.
46. Pirttila T., Soininen H., Mehta P.D., et al. Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Neurobiol. Aging 1997, 18(1):121-127.
47. Tiraboschi P., Hansen L.A., Masliah E., et al. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004, 62(11):1977-1983.
48. Sullivan P.M., Mezdour H., Quarfordt S.H., et al. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J. Clin. Invest. 1998, 102(1):130-135.
49. Buttini M., Yu G.-Q., Shockley K., et al. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 2002, 22(24):10539-10548.
50. Dolev I., Michaelson D.M. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc. Natl. Acad. Sci. 2004, 101(38):13909-13914.
51. Fitz N.F., Cronican A.A., Saleem M., et al. Abca1 deficiency affects Alzheimer[U+05F3]s disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J. Neurosci. 2012, 32(38):13125-13136.
52. Castellano J.M., Kim J., Stewart F.R., et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Trans. Med. 2011, 3(89). (89ra57).
53. Cerf E., Gustot A., Goormaghtigh E., et al. High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer[U+05F3]s disease. Fed. Am. Soc. Exp. Biol. 2011, 25(5):1585-1595.
54. Deane R., Sagare A., Hamm K., et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 2008, 118(12):4002-4013.
55. Esler W.P., Marshall J.R., Stimson E.R., et al. Apolipoprotein E affects amyloid formation but not amyloid growth in vitro: mechanistic implications for apoE4 enhanced amyloid burden and risk for Alzheimer[U+05F3]s disease. Amyloid 2002, 9(1):1-12.
56. Stratman N.C., Castle C.K., Taylor B.M., et al. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Chem. Phys. Lipids. 2005, 137(1-2):52-61.
57. Verghese P.B., Castellano J.M., Garai K., et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc. Natl. Acad. Sci. 2013, 110(19):E1807-E1816.
58. Bien-Ly N., Gillespie A.K., Walker D., et al. Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 2012, 32(14):4803-4811.
59. Kim J., Jiang H., Park S., et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J. Neurosci. 2011, 31(49):18007-18012.
60. Drzezga A., Grimmer T., Henriksen G., et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009, 72(17):1487-1494.
61. Lehmann M., Ghosh P.M., Madison C., et al. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. J. Neurol. Neurosurg. Psychiatry. 2014, 85(3):266-273.
62. Ossenkoppele R., Van Der Flier W.M., Zwan M.D., et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 2013, 80(4):359-365.
63. Rowe C.C., Ellis K.A., Rimajova M., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31(8):1275-1283.
64. Brecht W.J., Harris F.M., Chang S., et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 2004, 24(10):2527-2534.
65. Rohn T.T. Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer[U+05F3]s disease. Int. J. Mol. Sci. 2013, 14(7):14908-14922.
66. Buttini M., Akeefe H., Lin C., et al. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience 2000, 97(2):207-210.
67. Ladu M.J., Falduto M.T., Manelli A.M., et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 1994, 269(38):23403-23406.
68. Strittmatter W.J., Saunders A.M., Schmechel D., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. 1993, 90(5):1977-1981.
69. Strittmatter W.J., Saunders A.M., Goedert M., et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc. Natl. Acad. Sci. 1994, 91(23):11183-11186.
70. Aboud O., Mrak R.E., Boop F., et al. Apolipoprotein epsilon 3 alleles are associated with indicators of neuronal resilience. BMC Med. 2012, 10:35.
71. Dumanis S.B., Cha H.-J., Song J.M., et al. ApoE receptor 2 regulates synapse and dendritic spine formation. PLoS ONE 2011, 6(2):e17203.
72. Sen A., Alkon D.L., Nelson T.J. Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon. J. Biol. Chem. 2012, 287(19):15947-15958.
73. Arendt T., Schindler C., Bruckner M.K., et al. Plastic neuronal remodeling is impaired in patients with Alzheimer[U+05F3]s disease carrying apolipoprotein epsilon 4 allele. J. Neurosci. 1997, 17(2):516-529.
74. Bertrand P., Poirier J., Oda T., et al. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res. Mol. Brain Res. 1995, 33(1):174-178.
75. Pirttila T., Soininen H., Heinonen O., et al. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Brain Res. 1996, 722(1-2):71-77.
76. Ramassamy C., Averill D., Beffert U., et al. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer[U+05F3]s disease brain. Neurobiol. Dis. 2000, 7(1):23-37.
77. Ringman J.M., Elashoff D., Geschwind D.H., et al. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. Arch. Neurol. 2012, 69(6):757-764.
78. Schiele F., De Bacquer D., Vincent-Viry M., et al. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 2000, 152(2):475-488.
79. van Vliet P., Westendorp R.G.J., Eikelenboom P., et al. Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels. Neurology 2009, 73(9):681-687.
80. Johnson L.A., Olsen R.H.J., Merkens L.S., et al. Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner. Neurobiol. Dis. 2014, 64:150-162.
81. Riddell D.R., Zhou H., Atchison K., et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 2008, 28(45):11445-11453.
82. Ulrich J.D., Burchett J.M., Restivo J.L., et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol. Neurodegener. 2013, 8:13.
83. Vandal M., Alata W., Tremblay C., et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J. Neurochem. 2014, 129(3):516-526.
84. Wahrle S.E., Jiang H., Parsadanian M., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 2008, 118(2):671-682.
85. Bray N.J., Jehu L., Moskvina V., et al. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. Hum. Mol. Genet. 2004, 13(22):2885-2892.
86. Growdon W.B., Cheung B.S., Hyman B.T., et al. Lack of allelic imbalance in APOE epsilon 3/4 brain mRNA expression in Alzheimer[U+05F3]s disease. Neurosci. Lett. 1999, 272(2):83-86.
87. Lambert J.C., Perez-tur J., Dupire M.J., et al. Distortion of allelic expression of apolipoprotein E in Alzheimer[U+05F3]s disease. Hum. Mol. Genet. 1997, 6(12):2151-2154.
88. Arold S., Sullivan P., Bilousova T., et al. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer[U+05F3]s disease and apoE TR mouse cortex. Acta Neuropathol. 2012, 123(1):39-52.
89. Bekris L.M., Galloway N.M., Montine T.J., et al. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2010, 153B(2):409-417.
90. Siest G., Bertrand P., Qin B., et al. Apolipoprotein E polymorphism and serum concentration in Alzheimer[U+05F3]s disease in nine European centres: the ApoEurope study. ApoEurope group. Clin. Chem. Lab. Med. 2000, 38(8):721-730.
91. Matsui T., Ingelsson M., Fukumoto H., et al. Expression of APP pathway mRNAs and proteins in Alzheimer[U+05F3]s disease. Brain Res. 2007, 1161:116-123.
92. Yamagata K., Urakami K., Ikeda K., et al. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer[U+05F3]s disease. Dement. Geriatr. Cogn. Disord. 2001, 12(2):57-62.
93. Sastry P.S. Lipids of nervous tissue: composition and metabolism. Prog. Lipid Res. 1985, 24(2):69-176.
94. Handelmann G.E., Boyles J.K., Weisgraber K.H., et al. Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J. Lipid Res. 1992, 33(11):1677-1688.
95. Mauch D.H., Nagler K., Schumacher S., et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001, 294(5545):1354-1357.
96. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer[U+05F3]s disease. Trends Neurosci. 1994, 17(12):525-530.
97. Calderon F., Kim H.-Y. Role of RXR in neurite outgrowth induced by docosahexaenoic acid. Prostaglandins. Leukot. Essent. Fatty Acids 2007, 77(5-6):227-232.
98. Darios F., Davletov B. Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nature 2006, 440(7085):813-817.
99. Martin R.E., Wickham J.Q., Om A.S., et al. Uptake and incorporation of docosahexaenoic acid (DHA) into neuronal cell body and neurite/nerve growth cone lipids: evidence of compartmental DHA metabolism in nerve growth factor-differentiated PC12 cells. Neurochem. Res. 2000, 25(5):715-723.
100. Robson L.G., Dyall S., Sidloff D., et al. Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. Neurobiol. Aging 2010, 31(4):678-687.
101. Wurtman R.J., Cansev M., Ulus I.H. Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatide. J. Nutr. Health Aging 2009, 13(3):189-197.
102. He C., Qu X., Cui L., et al. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc. Natl. Acad. Sci. 2009, 106(27):11370-11375.
103. Arsenault D., Julien C., Tremblay C., et al. DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS ONE 2011, 6(2):e17397.
104. Ahmad A., Murthy M., Greiner R.S., et al. A decrease in cell size accompanies a loss of docosahexaenoate in the rat hippocampus. Nutr. Neurosci. 2002, 5(2):103-113.
105. Bousquet M., Saint-Pierre M., Julien C., et al. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. Fed. Am. Soc. Exp. Biol. 2008, 22(4):1213-1225.
106. Bousquet M., Gibrat C., Saint-Pierre M., et al. Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(8):1401-1408.
107. Wu A., Ying Z., Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 2008, 155(3):751-759.
108. Kawakita E., Hashimoto M., Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006, 139(3):991-997.
109. Igbavboa U., Hamilton J., Kim H.-Y., et al. A new role for apolipoprotein E: modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. J. Neurochem. 2002, 80(2):255-261.
110. Hayek T., Attias J., Smith J., et al. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. 1998, 31(4):540-544.
111. Smith J.D., Miyata M., Poulin S.E., et al. The relationship between apolipoprotein E and serum oxidation-related variables is apolipoprotein E phenotype dependent. Int. J. Clin. Lab. Res. 1998, 28(2):116-121.
112. Bassett C.N., Montine T.J. Lipoproteins and lipid peroxidation in Alzheimer[U+05F3]s disease. J. Nutr. Health Aging 2003, 7(1):24-29.
113. Chinnici C.M., Yao Y., Ding T., et al. Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice. Am. J. Pathol. 2005, 167(5):1371-1377.
114. Reich E.E., Markesbery W.R., Roberts L.J., et al. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer[U+05F3]s disease. Am. J. Pathol. 2001, 158(1):293-297.
115. Reich E.E., Montine K.S., Gross M.D., et al. Interactions between apolipoprotein E gene and dietary alpha-tocopherol influence cerebral oxidative damage in aged mice. J. Neurosci. 2001, 21(16):5993-5999.
116. Montine T.J., Morrow J.D. Fatty acid oxidation in the pathogenesis of Alzheimer[U+05F3]s disease. Am. J. Pathol. 2005, 166(5):1283-1289.
117. Lebbadi M., Julien C., Phivilay A., et al. Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer[U+05F3]s disease. J. Alzheimers Dis. 2011, 27(4):853-869.
118. Lim G.P., Calon F., Morihara T., et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 2005, 25(12):3032-3040.
119. Green K.N., Martinez-Coria H., Khashwji H., et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 2007, 27(16):4385-4395.
120. Calon F., Lim G.P., Yang F., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer[U+05F3]s disease mouse model. Neuron 2004, 43(5):633-645.
121. Calon F., Lim G.P., Morihara T., et al. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer[U+05F3]s disease. Eur. J. Neurosci. 2005, 22(3):617-626.
122. Perez S.E., Berg B.M., Moore K.A., et al. DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects. J. Neurosci. Res. 2010, 88(5):1026-1040.
123. Hooijmans C.R., Van der Zee CEEM, Dederen P.J., et al. DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol. Dis. 2009, 33(3):482-498.
124. Plourde M., Vohl M.-C., Vandal M., et al. Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE epsilon4 but not by the common PPAR-alpha L162V polymorphism in men. Br. J. Nutr. 2009, 102(8):1121-1124.
125. Samieri C., Lorrain S., Buaud B., et al. Relationship between diet and plasma long-chain n-3 PUFAs in older people: impact of apolipoprotein E genotype. J. Lipid Res. 2013, 54(9):2559-2567.
126. 13C-labelled DHA metabolism in elderly human subjects carrying the apoE epsilon4 allele. Br. J. Nutr. 2013, 110(10):1751-1759.
127. Edmond J. Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J. Mol. Neurosci. 2001, 16(2-3):181-193.
128. Mitchell R.W., Hatch G.M. Fatty acid transport into the brain: of fatty acid fables and lipid tails. Prostaglandins Leukot. Essent. Fatty Acids 2011, 85(5):293-302.
129. Hamilton J.A., Brunaldi K. A model for fatty acid transport into the brain. J. Mol. Neurosci. 2007, 33(1):12-17.
130. Ouellet M., Emond V., Chen C.T., et al. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. Neurochem. Int. 2009, 55(7):476-482.
131. Hamilton J.A. New insights into the roles of proteins and lipids in membrane transport of fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77(5-6):355-361.
132. Spector A.A. Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain. J. Mol. Neurosci. 2001, 16(2-3):159-165.
133. Weisgraber K.H., Innerarity T.L., Mahley R.W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 1982, 257(5):2518-2521.
134. Fullerton S.M., Shirman G.A., Strittmatter W.J., et al. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Exp. Neurol. 2001, 169(1):13-22.
135. Hafezi-Moghadam A., Thomas K.L., Wagner D.D. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am. J. Physiol. Cell Physiol. 2007, 292(4):C1256-C1262.
136. Kalaria R.N., Pax A.B. Increased collagen content of cerebral microvessels in Alzheimer[U+05F3]s disease. Brain Res. 1995, 705(1-2):349-352.
137. Tong X.-K., Nicolakakis N., Kocharyan A., et al. Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer[U+05F3]s disease. J. Neurosci. 2005, 25(48):11165-11174.
138. Zarow C., Barron E., Chui H.C., et al. Vascular basement membrane pathology and Alzheimer[U+05F3]s disease. Ann. NY Acad. Sci. 1997, 826:147-160.
139. Bourasset F., Ouellet M., Tremblay C., et al. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer[U+05F3]s disease. Neuropharmacology 2009, 56(4):808-813.
140. Gama Sosa M.A., Gasperi R.D., Rocher A.B., et al. Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer[U+05F3]s disease mutations. Am. J. Pathol. 2010, 176(1):353-368.
141. Salloway S., Gur T., Berzin T., et al. Effect of APOE genotype on microvascular basement membrane in Alzheimer[U+05F3]s disease. J. Neurol. Sci. 2002, 203-204:183-187.
142. Zipser B.D., Johanson C.E., Gonzalez L., et al. Microvascular injury and blood-brain barrier leakage in Alzheimer disease. Neurobiol. Aging 2007, 28(7):977-986.
143. Bell R.D., Winkler E.A., Singh I., et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485(7399):512-516.
144. Nishitsuji K., Hosono T., Nakamura T., et al. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J. Biol. Chem. 2011, 286(20):17536-17542.
145. Emery V.O. Alzheimer disease: are we intervening too late? Pro. J. Neural. Transm. 2011, 118:1361-1378.
146. Cummings J.L., Doody R., Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007, 69:1622-1634.
147. Aisen P.S., Vellas B., Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer[U+05F3]s disease. Nat. Rev. Drug Discov. 2013, 12:324.
148. Calon F. Omega-3 polyunsaturated fatty acids in Alzheimer[U+05F3]s Disease: key questions and partial answers. Curr. Alzheimer. Res. 2011, 8:470-478.